Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

1999

Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999;163(1):194-205.

Cesarman E, Mesri EA. Virus-associated lymphomas. Curr Opin Oncol. 1999;11(5):322-32.

Joe EK, Li VW, Magro CM, Arndt KA, Bowers KE. Diagnostic clues to dermatitis artefacta. Cutis. 1999;63(4):209-14.

Khatri KA, Ross V, Grevelink JM, Magro CM, Anderson RR. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol. 1999;135(4):391-7.

Walsh S, Murphy M, Silverman M, Odze R, Antonioli D, Goldman H, et al. p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis. Am J Pathol. 1999;155(5):1511-8.

Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin. 1999;17(3):537-60, viii.

Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 1999;18(11):3044-53.

Bao S, Chang MS, Auclair D, Sun Y, Wang Y, Wong WK, et al. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res. 1999;59(9):2023-8.

1998

Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem. 1998;273(37):24057-64.

Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 1998;157(4 Pt 1):1093-7.